WO2011027308A8 - Novel tumor markers - Google Patents

Novel tumor markers Download PDF

Info

Publication number
WO2011027308A8
WO2011027308A8 PCT/IB2010/053940 IB2010053940W WO2011027308A8 WO 2011027308 A8 WO2011027308 A8 WO 2011027308A8 IB 2010053940 W IB2010053940 W IB 2010053940W WO 2011027308 A8 WO2011027308 A8 WO 2011027308A8
Authority
WO
WIPO (PCT)
Prior art keywords
stage
tumor markers
progressed
expression
neoplastic disease
Prior art date
Application number
PCT/IB2010/053940
Other languages
French (fr)
Other versions
WO2011027308A1 (en
Inventor
Ralf Hoffmann
Edwin P. Romijn
Hugo M. Visser
Tim Hulsen
Original Assignee
Koninklijke Philips Electronics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics N.V. filed Critical Koninklijke Philips Electronics N.V.
Publication of WO2011027308A1 publication Critical patent/WO2011027308A1/en
Publication of WO2011027308A8 publication Critical patent/WO2011027308A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a tumor marker or group of tumor markers associated with the progression of a neoplastic disease from a less progressed stage to a more progressed stage, wherein the expression of the tumor markers is modified when comparing the expression in the less progressed stage and in the more progressed stage. The present invention further relates to a composition for diagnosing, detecting, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage comprising affinity ligands for the expression products of the tumor markers, to corresponding methods, and to the use of said tumor markers for detecting, diagnosing, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage. The present invention further relates to a corresponding immunoassay, to a method of identifying an individual for eligibility for a neoplastic disease therapy, as well as to a pharmaceutical composition based on the inhibition and/or activation of the expression of said tumor markers.
PCT/IB2010/053940 2009-09-03 2010-09-02 Novel tumor markers WO2011027308A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09169426.5 2009-09-03
EP09169426 2009-09-03
EP09169423 2009-09-03
EP09169423.2 2009-09-03

Publications (2)

Publication Number Publication Date
WO2011027308A1 WO2011027308A1 (en) 2011-03-10
WO2011027308A8 true WO2011027308A8 (en) 2011-12-15

Family

ID=43064688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/053940 WO2011027308A1 (en) 2009-09-03 2010-09-02 Novel tumor markers

Country Status (1)

Country Link
WO (1) WO2011027308A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5783909B2 (en) 2009-12-16 2015-09-24 積水メディカル株式会社 Diagnostic method of malignant tumor
JP5808054B2 (en) 2009-12-25 2015-11-10 中外製薬株式会社 Anticancer drug target search and screening method using non-human animal model transplanted with NOG established cancer cell line
CN103328626B (en) 2010-10-06 2017-02-08 中外制药株式会社 Cancer stem cell mass and process for production thereof
WO2013035824A1 (en) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド Cancer stem cell isolation
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
PL3253800T3 (en) 2015-03-27 2021-08-23 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090580A1 (en) * 2001-05-03 2002-11-14 National Cancer Centre Of Singapore Pte Ltd Identifying liver cancer by detecting aberrant expression of insulin like growth factor binding protein
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
KR100953821B1 (en) * 2007-12-03 2010-04-21 순천향대학교 산학협력단 Biomarker for diagnosing asthma and therapeutic agent of asthma controlling expression of vitamin D binding protein

Also Published As

Publication number Publication date
WO2011027308A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011027310A8 (en) Novel tumor markers
WO2011027308A8 (en) Novel tumor markers
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2007047408A3 (en) Promac signature application
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2008023840A3 (en) Prognostic markers and therapeutic targets for lung cancer
WO2011027311A3 (en) Novel tumor markers
WO2007000320A3 (en) Method for diagnosing rheumatic diseases
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2011073901A8 (en) Novel tumor markers
WO2007023191A3 (en) Polypeptide marker for the diagnosis of bladder cancer
WO2009019369A3 (en) I-plastin assay method for the in vitro diagnosis of colorectal cancer
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2010131193A8 (en) Phosphodiesterase 9a as prostate cancer marker

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10760031

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10760031

Country of ref document: EP

Kind code of ref document: A1